# Cardinal Health, Inc. (CAH) Stock Analysis: A Healthcare Powerhouse with a Promising 3.99% Upside

- Link: https://www.directorstalkinterviews.com/cardinal-health-inc-cah-stock-analysis-a-healthcare-powerhouse-with-a-promising-3-99-upside/4121232517
- Published: 2025-12-29T11:18:02+00:00
- Author: Madison Wilson

Cardinal Health, Inc. (NYSE: CAH) stands out as a stalwart in the healthcare sector,
specifically within the medical distribution industry. With a robust market capitalization
of $49.49 billion, Cardinal Health operates as a comprehensive healthcare services
and products company in the United States and on an international scale. Its dual-
segment operations, encompassing Pharmaceutical and Specialty Solutions, as well
as Global Medical Products and Distribution, position the company as a critical 
player in the distribution of pharmaceutical and medical products.

Currently trading at $208.29, Cardinal Health’s stock has seen a remarkable 52-week
range from $117.92 to $213.73. This price stability is bolstered by a 50-day moving
average of $194.11 and a 200-day moving average of $161.18, indicating a strong 
upward momentum. The RSI (Relative Strength Index) stands at 83.45, suggesting that
the stock is in overbought territory, which may warrant a closer look for potential
entry points.

Despite the absence of a trailing P/E ratio, the forward P/E stands at 18.79, reflecting
investor optimism about future earnings growth. A noteworthy revenue growth of 22.40%
underscores Cardinal Health’s ability to expand its top line significantly, even
though specific net income figures weren’t disclosed. The company’s EPS (Earnings
Per Share) of 6.62 further accentuates its profitability potential, while a free
cash flow of approximately $4.7 billion highlights its strong operational cash generation
capabilities.

For income-focused investors, Cardinal Health offers a dividend yield of 0.98%, 
with a prudent payout ratio of 30.66%. This indicates that the company maintains
a balanced approach to rewarding shareholders while retaining sufficient capital
for reinvestment and growth.

Analyst sentiment towards Cardinal Health is predominantly positive, with 12 buy
ratings, 4 hold ratings, and a single sell rating. The target price range spans 
from $167.00 to $243.00, with an average target of $216.60, suggesting a potential
upside of about 3.99%. This optimistic outlook is reinforced by the company’s strategic
positioning in the healthcare supply chain and its comprehensive portfolio of services,
from pharmaceutical distribution to medical product manufacturing.

Cardinal Health’s technical indicators further signify its robust performance. The
MACD (Moving Average Convergence Divergence) of 2.65, above the signal line of 2.46,
indicates a bullish trend. Investors should, however, remain vigilant to potential
market corrections, given the stock’s current overbought status as per the RSI.

Incorporated in 1979 and headquartered in Dublin, Ohio, Cardinal Health continues
to innovate and expand its reach in the healthcare sector. The company’s ability
to provide customized solutions across various healthcare settings—from hospitals
and pharmacies to home-based patient care—cements its role as a leader in healthcare
services and products distribution.

Investors considering adding Cardinal Health to their portfolios should weigh the
company’s strong fundamentals against the broader market conditions. With its significant
market presence, substantial free cash flow, and positive analyst outlook, Cardinal
Health offers a compelling investment case, particularly for those seeking exposure
to the healthcare sector’s growth potential.

Share on:
